ESTRO PT 2018

NRG: (Radiation Therapy Oncology Group – integrated into new organization “NRG” (= NASBP, RTOG, GOG):

CNS: RTOG-1205: Recurrent GBM. Randomized phase III trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone. Open. Permitting protons. Accrual 180 patients. Prescription: 35 Gy in 10 fractions. Randomization is between bevacizumab plus radiation versus bevacizumab alone, at the time of next recurrence re-irradiation will be permitted. Recently completed accrual. CLOSED

NRG-BN001 : Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma . Open

Hypothesis: prolonged overall survival from 16 months (standard Dose of 60 Gy) to 22 months Randomization between dose, not modality. However, modalities will be compared Accrual: 576 patients. Activated 10/2014